-- Abercrombie, AVI BioPharma, Hartford: U.S. Equity Movers
-- B y   L u   W a n g
-- 2012-04-02T20:22:15Z
-- http://www.bloomberg.com/news/2012-03-30/analog-devices-groupon-medtronic-u-s-equity-preview.html
Shares of the following companies
had unusual moves in U.S. trading. Stock symbols are in
parentheses, and prices are as of 4 p.m. in  New York .  Abercrombie & Fitch Co. (ANF)   climbed 4.1 percent, the
most since Feb. 15, to $51.62. The teen-clothing retailer was
raised to buy from hold at Brean Murray Carret & Co.  Amazon.com Inc. (AMZN)   fell 2.2 percent, the second
biggest retreat in the  S&P 500 , to $198.05. The largest Internet
retailer was cut to neutral from buy at Bank of America Corp. on
concern analysts’ earnings expectations are too high.  AVI BioPharma Inc. (AVII)   tumbled 28 percent, the most
since May 2006, to $1.11. The biotechnology company said a study
showed its experimental drug for Duchenne muscular dystrophy
requires longer treatment to demonstrate benefit.  Avon Products Inc. (AVP)   surged 17 percent, the most
since July 2008, to $22.70. Coty Inc. offered to buy the door-
to-door cosmetics seller conducting an internal bribery probe,
for about $10 billion. The cash proposal of $23.25 a share is 20
percent higher than Avon’s closing price on March 30. Coty has
said it has held “extensive discussions” about financing a
deal.  Express Scripts Inc. (ESRX)   rose 2.4 percent to $55.50,
the highest price since July 26. The pharmacy benefits manager’s
$29.1 billion bid for rival  Medco Health Solutions Inc. (MHS)  
won unconditional approval from U.S. antitrust regulators,
clearing the way to create the biggest manager of prescription-
drug benefits for corporate and government clients.  Groupon Inc. (GRPN)  (GRPN US) slid 17 percent, the most since its
initial public offering in November, to $15.28. The largest
provider of daily deals online reported a “material weakness”
in its financial controls and said fourth-quarter results were
worse than previously stated because of higher refunds to
merchants. That cut revenue in the period by $14.3 million to
$492.2 million. Groupon was also downgraded to neutral from buy
at Bank of America Corp.  Hartford Financial Services Group Inc. (HIG)   rose 4.1
percent, the most since March 15, to $21.95. The insurer being
pressured by investor  John Paulson  to break up said it will pay
about $2.43 billion to buy back debt and warrants issued to
Allianz SE. Chief Executive Officer Liam McGee plans to issue
senior notes and junior subordinated debt as part of a strategy
to improve financial flexibility, according to a statement.  Keryx Biopharmaceuticals Inc. (KERX)   sank 65 percent,
the most since March 2008, to $1.74, The developer of treatments
for cancer and renal disease and  Aeterna Zentaris (AEZS)   said
perifosine didn’t meet the primary goal of improving survival
when combined with  Roche Holding AG’s (ROG)   Xeloda. Aeterna
plunged 66 percent to 73 cents.  Roundy’s Inc. (RNDY)  (RNDY US) gained 7.6 percent to $11.51, the
highest price since it went public in February. The grocery-
store chain was added to the Russell 2000 Index.  Theravance Inc. (THRX)   advanced 19 percent, the most
since October 2008, to $23.29.  GlaxoSmithKline Plc (GSK)  
agreed to pay $212.9 million to boost its stake in the maker of
treatments for respiratory disorders and bacterial infections to
26.8 percent, deepening ties with the company that developed its
experimental asthma medicine Relovair.  Threshold Pharmaceuticals Inc. (THLD)   declined 5.8
percent, the most since Feb. 28, to $8.29. The biotechnology
company said that a Phase 2b trial for its TH-302 pancreatic
cancer drug met its primary efficacy endpoint.  Towerstream Corp. (TWER)   gained 9.9 percent to $5.22,
the highest price since July 7. The Middletown, Rhode Island-
based wireless broadband provider has signed a Wi-Fi agreement
with a national wireless carrier that uses its current and
future rooftop assets, the company said in filing.  Willbros Group Inc. (WG)   climbed 21 percent, the most
since October 2003, to $3.93. The oil-industry contractor
forecast 2012 revenue of as much as $1.9 billion, above the
average analyst estimate of $1.79 billion.  To contact the reporter on this story:
 Lu Wang  in New York at   lwang8@bloomberg.net .  To contact the editor responsible for this story:
Nick Baker at 
 nbaker7@bloomberg.net  